<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain>The <z:mp ids='MP_0002169'>wild-type</z:mp> <z:hpo ids='HP_0002667'>Wilms tumor</z:hpo> gene, WT1, is overexpressed in <z:hpo ids='HP_0002863'>myelodysplastic syndrome</z:hpo> (<z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">MDS</z:e>) as well as <z:hpo ids='HP_0004808'>acute myeloid leukemia</z:hpo> </plain></SENT>
<SENT sid="1" pm="."><plain>In a phase I clinical trial of biweekly vaccination with HLA-A*2402-restricted WT1 <z:chebi fb="7" ids="16670">peptide</z:chebi> for these <z:e sem="disease" ids="C0006826" disease_type="Neoplastic Process" abbrv="">malignancies</z:e>, 2 patients with <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">MDS</z:e> developed severe <z:mp ids='MP_0000221'>leukocytopenia</z:mp> in association with a reduction in leukemic blast cells and levels of WT1 <z:chebi fb="5" ids="33699">messenger RNA</z:chebi> (<z:chebi fb="2" ids="33699">mRNA</z:chebi>) after only a single vaccination with 0.3 mg of WT1 <z:chebi fb="7" ids="16670">peptide</z:chebi> </plain></SENT>
<SENT sid="2" pm="."><plain>These results indicated that the WT1-specific cytotoxic T-lymphocytes (CTLs) elicited by WT1 vaccination eradicated the WT1-expressing transformed stem or progenitor cells and that <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">MDS</z:e> patients with little <z:mpath ids='MPATH_458'>normal</z:mpath> hematopoiesis required a new strategy of WT1 vaccination to avoid severe <z:mp ids='MP_0000221'>leukocytopenia</z:mp> </plain></SENT>
<SENT sid="3" pm="."><plain>We describe the first trial for a 57-year-old male patient with <z:hpo ids='HP_0011010'>chronic</z:hpo> myelomonocytic <z:hpo ids='HP_0001909'>leukemia</z:hpo> who was vaccinated biweekly with a small quantity (5 microg/body) of WT1 <z:chebi fb="7" ids="16670">peptide</z:chebi> </plain></SENT>
<SENT sid="4" pm="."><plain>After the start of vaccination, the leukocyte and monocyte counts (13,780/microL and 1930/microL, respectively) gradually decreased to within the <z:mpath ids='MPATH_458'>normal</z:mpath> range in association with a reduction in the WT1 <z:chebi fb="2" ids="33699">mRNA</z:chebi> level </plain></SENT>
<SENT sid="5" pm="."><plain>Simultaneously, the percentage of WT1-specific CTLs as measured by the HLA-WT1 tetramer assay increased </plain></SENT>
<SENT sid="6" pm="."><plain>This case demonstrates for the first time that vaccination with as little as 5 microg of WT1 <z:chebi fb="7" ids="16670">peptide</z:chebi> can induce WT1-specific immune responses and resultant clinical responses </plain></SENT>
</text></document>